Zomedica logo

ZomedicaNYSE American: ZOM

Profile

Sector:

Healthcare

Country:

United States

IPO:

21 November 2017

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$126.34 M
-77%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
31%vs. sector
-99%vs. 3y high
59%vs. sector

Price

after hours | Fri, 25 Oct 2024 23:59:34 GMT
$0.13+$0.01(+5.50%)

Dividend

No data over the past 3 years
$6.13 M-$23.93 M

Analysts recommendations

Institutional Ownership

ZOM Latest News

Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET
accesswire.com23 October 2024 Sentiment: POSITIVE

ANN ARBOR, MI / ACCESSWIRE / October 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its thirdquarter ended September 30, 2024.

Zomedica Announces Sponsorship of Educational Presentations at the Fetch Coastal Conference
https://www.accesswire.com/viewarticle.aspx?id=931555&lang=en15 October 2024 Sentiment: POSITIVE

Leading veterinary experts to present educational programs featuring Zomedica product applications at the Fetch dvm360 Veterinary Conference ANN ARBOR, MI / ACCESSWIRE / October 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch Coastal, formerly the Atlantic Coast Veterinary Conference, in Atlantic City, NJ from October 14-16 , 2024. "The Fetch Coastal conference is a cornerstone event in the veterinary industry for the east coast, bringing together the brightest minds and latest innovations," remarked Nicole Westfall, Zomedica's Senior Vice President of Marketing.

Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe
accesswire.com03 October 2024 Sentiment: POSITIVE

Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution partnership in Europe with Grovet, a leading equine-focused veterinary distributor. The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet® and TRUFORMA product platforms throughout most of Europe.

Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
accesswire.com11 September 2024 Sentiment: POSITIVE

Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce the completion of renovations at its 30,000-square-foot manufacturing, distribution, and research and development (R&D) facility in Plymouth, Minnesota. Highlights of the renovation include: Expanded cleanroom for manufacturing operations Installation and validation of new automated line to produce TRUFORMA® consumable cartridges Improved distribution facilities for more efficient and streamlined shipping of TRUFORMA cartridges "With the steady growth of our TRUFORMA product line, these facility renovations, and new automated production equipment have increased manufacturing capacity which we believe will meet increasing demand for TRUFORMA cartridges for years to come," stated Larry Heaton, Zomedica's Chief Executive Officer.

Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
accesswire.com05 September 2024 Sentiment: POSITIVE

CE Mark approval opens European market for TRUVIEW system ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced it has secured the CE Mark for its revolutionary TRUVIEW™ digital microscopy and telepathology platform. The CE Mark certification affirms the system's compliance with the stringent health, safety, and environmental standards required by the European Union, enabling Zomedica to commercialize the TRUVIEW microscope across the European Economic Area (EEA).

Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
accesswire.com20 August 2024 Sentiment: POSITIVE

Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch dvm360 Veterinary Conference, taking place in Kansas City, MO, from August 23-25, 2024. "We are proud to continue our partnership with the Fetch dvm360 series of veterinary Continuing Education programs," commented Nicole Westfall, Zomedica's Senior Vice President of Marketing.

Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: NEUTRAL

Zomedica Corp. (NYSE:ZOM ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Andrew Rem - Odinson Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Zomedica Q2 2024 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, August 14, 2024.

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
accesswire.com14 August 2024 Sentiment: POSITIVE

Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024. "We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date.

Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
accesswire.com14 August 2024 Sentiment: POSITIVE

SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica ® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the latest expansion of its sales reach into Costa Rica. SIRE Veterinario, S.A.

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
accesswire.com01 August 2024 Sentiment: POSITIVE

ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ended June 30, 2024.

  • 1(current)

What type of business is Zomedica?

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

What sector is Zomedica in?

Zomedica is in the Healthcare sector

What industry is Zomedica in?

Zomedica is in the Medical Devices industry

What country is Zomedica from?

Zomedica is headquartered in United States

When did Zomedica go public?

Zomedica initial public offering (IPO) was on 21 November 2017

What is Zomedica website?

https://www.zomedica.com

Is Zomedica in the S&P 500?

No, Zomedica is not included in the S&P 500 index

Is Zomedica in the NASDAQ 100?

No, Zomedica is not included in the NASDAQ 100 index

Is Zomedica in the Dow Jones?

No, Zomedica is not included in the Dow Jones index

When was Zomedica the previous earnings report?

No data

When does Zomedica earnings report?

The next expected earnings date for Zomedica is 13 November 2024